GAPDH

Across TCGA pan-cancer cohorts, GAPDH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GAPDH data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GAPDH mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GAPDH expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where GAPDH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.505	0.888	<.001	65	view →
HNSC	DFS	Median	III,IV	0.912	0.661	<.001	29	view →
CCRCC	OS	Quartile	All	0.656	0.905	.006	22	view →
GBM	OS	Tertile	All	0.270	0.529	.004	16	view →
LSCC	OS	Median	All	0.800	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GAPDH–LUAD (OS)

Open the LUAD breakdown →